Company profile
SILENCE THERAPEUTICS PLC
NASDAQ:SLNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZERLASIRAN | phase2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04559971 | — | completed | 2020-09-03 | 2021-03-23 | Silence Therapeutics plc | A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers |
| NCT04718844 | phase1 | completed | 2021-04-14 | 2023-05-23 | Silence Therapeutics plc | A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome |
| NCT01808638 | phase1_2 | completed | 2013-03-01 | 2015-08-01 | Silence Therapeutics GmbH | Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) |
| NCT05537571 | phase2 | completed | 2022-12-13 | 2024-01-11 | Silence Therapeutics plc | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events |
| NCT00938574 | phase1 | completed | 2009-06-01 | 2012-07-01 | Silence Therapeutics GmbH | Study With Atu027 in Patients With Advanced Solid Cancer |
FDA applications (0)
No records yet.